Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | CHKA | P35790 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31082092 | 0.97 | ALDH1A1 (0.60) | ALDH1A1HTTSMN1; SMN2HRH3CHKA | |
| SCHEMBL20680172 | 0.87 | CHKA (0.57) | ALDH1A1HTTCHKANCF1KDM4E | |
| SCHEMBL31082081 | 0.86 | HRH3 (0.51) | ALDH1A1HTTSMN1; SMN2HRH3NCF1 | |
| SCHEMBL29954738 | 0.85 | ALDH1A1 (0.68) | ALDH1A1HTTSMN1; SMN2HRH3POLB | |
| SCHEMBL19211728 | 0.84 | ALDH1A1 (0.48) | ALDH1A1HTTHRH3CHKAKDM4E | |
| SCHEMBL19211653 | 0.83 | ALDH1A1 (0.45) | ALDH1A1HTTSMN1; SMN2CHKAKDM4E | |
| SCHEMBL19211684 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HTTCHKAKDM4E | |
| SCHEMBL790908 | 0.81 | HRH3 (0.52) | ALDH1A1HTTSMN1; SMN2HRH3POLB | |
| SCHEMBL28192273 | 0.80 | ALDH1A1 (0.96) | ALDH1A1HTTSMN1; SMN2HRH3CHKA | |
| SCHEMBL789600 | 0.80 | HRH3 (0.55) | ALDH1A1HTTSMN1; SMN2HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884046-B | Chemical compounds as inhibitors of kinase activity | 葛兰素史克知识产权开发有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-10793559-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-06 | — | — | US | disclosed |
| US-10793559-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-06 | — | — | US | disclosed |
| EP-3414228-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| EP-3414228-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| US-20200071311-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-20200071311-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-10457674-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-29 | — | — | US | disclosed |
| US-10457674-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-29 | — | — | US | disclosed |
| US-20190040051-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
| US-20190040051-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
| EP-3414228-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017137535-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017137535-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793559-B2 | Chemical compounds | PIK3CA, PIK3CD, PIK3C2B | ALDH1A1 1313/4885HTT 3137/4885SMN1; SMN2 4722/4885 |
| US-20190040051-A1 | CHEMICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | ALDH1A1 1313/4885HTT 3137/4885SMN1; SMN2 4722/4885 |
| US-20200071311-A1 | CHEMICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | ALDH1A1 1313/4885HTT 3137/4885SMN1; SMN2 4722/4885 |
| US-10457674-B2 | Chemical compounds | PIK3CA, PIK3CD, PIK3C2B | ALDH1A1 1313/4885HTT 3137/4885SMN1; SMN2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.